|
|
|
26.03.26 - 15:54
|
AI-powered Benefits Platform Origin Raises $30 Million Series A+, Bringing Total Funding to Over $50 Million to Tackle the Growing Inefficiency of Global Benefits Spend (Business Wire)
|
|
|
New funding will accelerate Origin's Enterprise Benefits Intelligence platform - which was co-created with multinational organisations including Pfizer, Comcast and BP
“It's a problem the benefits industry has been trying to solve for 15 years”, says Origin CEO Chris Bruce, “which is only possible thanks to AI.”LONDON--(BUSINESS WIRE)--Origin, the AI native platform reshaping how global organisations manage employee benefits, today announced a $30 million Series A+ funding round. This brings the company's total funding to over $50 million within twelve months. Origin helps organisations to manage one of the largest, least visible areas of workforce spend - global benefits. Its platform identifies inefficiencies, streamlines benefits operations and improves employee experience at scale.
The Series A+ is led by Notion Capital, which also participated in Origin's Series A round. Felix Capital, which led the Series A round, Acadian Ventures, and all existing investors are participating in the Seri...
|
|
|
26.03.26 - 13:00
|
Income Investors Face a Hard Truth About Pfizer’s Payout Safety (24/7 Wall St.)
|
|
|
Pfizer (NYSE: PFE) is one of the most widely held dividend stocks among retirement investors. The stock currently yields 6.3%, well above most fixed-income alternatives. But a high yield can be a warning sign, and right now Pfizer's payout mechanics deserve a hard look. Dividend Snapshot Metric Value Annual Dividend $1.72/share Dividend Yield 6.3% Quarterly ... Income Investors Face a Hard Truth About Pfizer's Payout Safety
The post Income Investors Face a Hard Truth About Pfizer's Payout Safety appeared first on 24/7 Wall St.....
|
|
|
|
|
25.03.26 - 17:24
|
This 6.5%‑Yielding Dividend Payer is Sitting on a Breakthrough Investors Haven′t Priced In (24/7 Wall St.)
|
|
|
It's rare to get such a massive high-yielder that's also positioning itself for long-term growth. Of course, shares of Pfizer (NYSE:PFE) have faced immense challenges in the years that followed its COVID era peak. And while some rockier days might still be up ahead, the company has a lot of promising innovations in the pipeline. ... This 6.5%‑Yielding Dividend Payer is Sitting on a Breakthrough Investors Haven't Priced In
The post This 6.5%‑Yielding Dividend Payer is Sitting on a Breakthrough Investors Haven't Priced In appeared first on 24/7 Wall St.....
|
|
|
25.03.26 - 08:01
|
Schock bei Valneva: Impfstoff-Dämpfer lässt Aktie abstürzen ? wie geht es jetzt weiter? (Ariva)
|
|
|
Ein Hoffnungsträger stürzt ab: Ein einziger statistischer Wert bringt die Investmentstory ins Wanken ? und lässt Anleger panisch fliehen. Ist das nur ein Rückschlag oder der Anfang vom Ende? Für den Impfstoffentwickler Valneva ist es ein rabenschwarzer Tag an der Börse. Die Aktie bricht zeitweise um rund 40 Prozent ein – ausgelöst durch die lang erwarteten Phase-3-Daten zum Lyme-Borreliose-Impfstoffkandidaten VLA15, der gemeinsam mit Pfizer entwickelt wird. Auf den ......
|
|
|
24.03.26 - 15:54
|
Pfizer Could Hit $36 by Year-End as Analysts See 2-to-1 Payoff on Key Prostate Cancer Trial (24/7 Wall St.)
|
|
|
Pfizer (NYSE:PFE) has quietly built momentum in 2026, with shares up 6.61% year-to-date and 2.70% over the past year. The stock is currently trading near $26.84 but remains well below its 52-week high of $27.94. Wall Street consensus sits at a cautious average price target of $28.14, reflecting a predominantly Hold posture across 28 analyst ... Pfizer Could Hit $36 by Year-End as Analysts See 2-to-1 Payoff on Key Prostate Cancer Trial
The post Pfizer Could Hit $36 by Year-End as Analysts See 2-to-1 Payoff on Key Prostate Cancer Trial appeared first on 24/7 Wall St.....
|
|
|
24.03.26 - 15:06
|
Pfizer Invites Public to View and Listen to Webcast of May 5 Conference Call with Analysts (Business Wire)
|
|
|
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10:00 a.m. EDT on Tuesday, May 5, 2026. The purpose of the call is to provide an update on Pfizer's results, as reflected in the company's First Quarter 2026 Performance Report, to be issued that morning.
To view and listen to the webcast and view the Performance Report, visit our web site at www.pfizer.com/investors. Information on accessing and registering for the webcast will be available at www.pfizer.com/investors beginning today. Participants are advised to register in advance of the conference call.
You can also listen to the conference call by dialing either 800-456-4352 in the United States and Canada or 785-424-1086 outside of the United States and Canada. The passcode is “74607”.
The transcript and webcast replay of the call will be made available on our web site at www.pfizer.com/investors within 24 hours after the en...
|
|
|
|
|
24.03.26 - 11:42
|
Pfizer Buy (DPA-AFX)
|
|
|
NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat die Einstufung für Pfizer auf "Buy" mit einem Kursziel von 34 US-Dollar belassen. Auch wenn die Phase-III-Studie des Pharmakonzerns zum Lyme-Impfstoff den vorab definierten primären Endpunkt ......
|
|
|
|
|
|
|
|
|
|
|
23.03.26 - 13:45
|
Valneva-Aktie -40%: Absturz mit Ansage! (Sharedeals)
|
|
|
Der französisch-österreichische Impfstoffentwickler Valneva und sein US-Partner Pfizer haben erste Ergebnisse ihrer entscheidenden Phase-3-Studie zum Lyme-Borreliose-Impfstoff VLA15 veröffentlicht – doch die Reaktion an der Börse fällt deutlich negativ aus. Während die Unternehmen weiterhin eine Zulassung anstreben, reagierten Investoren enttäuscht: Die Aktie von Valneva bricht zeitweise um rund 40% ein. Studie verfehlt primären Endpunkt Der Impfstoffkandidat […]
The post Valneva-Aktie -40%: Absturz mit Ansage! first appeared on sharedeals.de....
|
|
|
23.03.26 - 13:33
|
Valneva-Aktie crasht brutal – die Hintergründe (Der Aktionaer)
|
|
|
Lange Gesichter bei den Aktionären von Valneva. Das Papier der europäischen Impfstoff-Hoffnung crasht zur Stunde um rund 40 Prozent. Für eine Enttäuschung sorgen die lang erwarteten Phase-3-Studiendaten zum Lyme-Borreliose-Impfstoffkandidaten LB6V (vormals VLA15), der zusammen mit dem US-Pharma-Riesen Pfizer entwickelt wird....
|
|
|
|
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
